WARNING LETTER
YangZhou SuXiang Medical Instrument Co., Ltd.
MARCS-CMS 686655 —
July 08, 2024
Delivery Method:
VIA EMAIL WITH READ RECEIPT
Product:
Drugs
Recipient:
Recipient Name
Mr. Bian Xiangli
Recipient Title
Managing Director
YangZhou SuXiang Medical Instrument Co., Ltd.
West of Baoyuan Road, Industrial Concentration Zone
Anyi Town
Baoying Xian
Yangzhou Shi
Jiangsu Sheng
,
China
Issuing Office:
Center for Drug Evaluation and Research (CDER)
United States
Warning Letter
320-24-50
July 8, 2024
Dear Mr. Xiangli:
Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 15, 2022 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, YangZhou SuXiang Medical Instrument Co., Ltd., 3014321771, at West of Baoyuan Road, Industrial Concentration Zone, Anyi Town, BaoYing County, Yangzhou City, China.
This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).
Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).
Following review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:
1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).
Your firm manufactured OTC drug products including
(b)(4)
Pads intended for
(b)(4)
. Based on the records and information provided, you did not demonstrate that you are adequately testing the identity of incoming components used in the manufacture of your drug products.
Without adequate testing you do not have scientific evidence that your raw materials conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.
The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document,
Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol
at https://www.fda.gov/media/173005/download.
2. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).
Based on the information provided, you did not demonstrate that your manufacturing
processes are reproducible and controlled to yield a product of uniform character and quality. For example, we requested the manufacturing process validation reports for your products. The reports you provided were incomplete. In addition, you distributed your products to U.S. markets prior to the performing process validations.
Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies includes intensive monitoring and testing of throughout each significant process stage to characterize intra-batch variation and evaluates batches to determine whether an initial state of control has been established.
Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.
We also note that your Quality Unit (QU) did not ensure that your manufacturing processes were adequately validated and in a state of control before releasing your OTC products for distribution to the U.S. market.
3. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).
Based on the records and information provided, you did not demonstrate that you conducted adequate finished drug product testing on your drug products. For example, you did not provide analytical test data to demonstrate you adequately test products before releasing them for distribution.
Full release testing, including strength and identity testing of the active ingredient, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your drug products conform to appropriate specifications before release.
CGMP Consultant Recommended
If your firm intends to resume manufacturing drugs for the U.S. market, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements before resuming drug manufacturing operations. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPAs before you pursue resolution of your firm’s compliance status per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.
Conclusion
The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.
FDA placed your firm on Import Alert 66-40 on July 1, 2024.
Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.
Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at YangZhou SuXiang Medical Instrument Co., Ltd. at West of Baoyuan Road, Industrial Concentration Zone, Anyi Town, BaoYing County, Yangzhou City, Jiangsu Province, China into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission.
This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.
Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014321771 and ATTN: Carlos Gonzalez.
Sincerely,
/S/
Francis Godwin
Director
Office of Manufacturing Quality
Office of Compliance
Center for Drug Evaluation and Research
Content current as of:
07/16/2024
Regulated Product(s)
Drugs